GlassScriptPhysician profile
John Fuller
NPI 1720469174
$5,708.05
in general payments reported to CMS, 2019-2025
12 companies · $1,797 in 2025
The $1,797 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $174 · 2022: $1,628 · 2023: $1,366 · 2024: $744 · 2025: $1,797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,223 · Food and Beverage: $1,683.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,223.28 |
| Food and Beverage | $1,683.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $1,581.33 | 2021-2023 | Evos, Evos Mini, Hat-Trick |
| Arthrex, INC. | $1,347.55 | 2024-2025 | |
| Mvp Orthopedics INC | $1,212.71 | 2022 | |
| Coastal Medical Technologies LLC | $816.77 | 2024-2025 | |
| Stryker Corporation | $474.25 | 2022-2025 | Reunion, T2 Alpha, Gamma |
| Endo Pharmaceuticals INC. | $86.96 | 2022 | |
| Acumed LLC | $66.66 | 2022 | |
| Integra Lifesciences Corporation | $42.37 | 2023 | Tenoglide |
| Heron Therapeutics, INC. | $26.37 | 2025 | Zynrelef |
| Axogen | $21.70 | 2024 | Axoguard Ha+ Nerve Protector, Axoguard Nerve Cap, Axoguard Nerve Protector |
| Fidia Pharma USA INC. | $18.30 | 2024 | Triluron, Hymovis, Hyalgan |
| Orthofix Medical, INC. | $13.08 | 2024 | Physio-Stim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Fuller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.